Merck & Co. has delivered a one-two legal punch against Halozyme Therapeutics, clearing major commercialization hurdles for ...
Though the quest to locate the regulator’s next commissioner hit a snag this week, the FDA has nevertheless been bringing ...
The FDA's complete response letter for Summit Therapeutics and Akeso's ivonescimab reveals more grievances than just an ...
Novo will trim 215 jobs reporting to its New Jersey headquarters starting in February as part of a "redesign" of its U.S.
Facing an extended drought of options, patients with type 3 Gaucher disease (GD3) are getting a new treatment that's also the ...
But regulatory approval is, in many ways, just the beginning of a complex journey to market for these companies, should their ...
After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the ...
The FDA has slammed Johnson & Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma ...
Speaking on a press call ahead of Thursday’s investor presentation, CEO Vas Narasimhan attributed the lower growth target to ...
Beren Therapeutics has officially seen a cyclodextrin therapy across the finish line, scoring an FDA approval in Niemann-Pick disease type C (NPC) that’s over a decade in the making.
Abu Dhabi-based Arcera Life Sciences has pledged more than $1 billion in totality for the rights to potentially take ...
Underscoring how crowded the U.S. market for generalized myasthenia gravis (gMG) has become, the FDA on Wednesday approved ...